Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Drug-pricing promises are colliding with reality: A month in, the TrumpRx platform still includes only a limited number of drugs and it’s unclear if the site is being widely used, STAT’s Daniel Payne writes.
Also today, Lilly is experimenting with employer subsidies for Zepbound outside insurance.Continue to STAT+ to read the full story…